Close menu




November 17th, 2021 | 11:13 CET

ThyssenKrupp, Memiontec, Everfuel - Everything is connected

  • Investments
Photo credits: pixabay.com

If you take a closer look at the results of the COP26 World Climate Conference in Glasgow, you get the feeling that the world has moved a little closer together in terms of climate protection. However, it is 5 to 12 to reach the 1.5-degree global warming target. The consequences of failure are dramatic. Climate change is leading to less water and poorer water quality. Globally, 2.2 billion people currently lack access to safe drinking water. The rising trend is alarming.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: THYSSENKRUPP AG O.N. | DE0007500001 , Memiontec Holdings Limited | SGXE56008290 , Everfuel A/S | DK0061414711

Table of contents:


    Dramatic development

    Global water consumption today is six times higher than it was 100 years ago. Population growth, economic boom and changing consumption patterns mean that water consumption rises by about 1% per year. Up to 90% of all wastewater worldwide is discharged untreated, polluting the environment and drinking water supplies. In addition, climate change is leading to less water and poorer water quality. On the other hand, sustainable water management has a positive effect on climate change. The World Water Report 2020, prepared by UNESCO on behalf of the United Nations, demonstrates this.

    Decades of development

    Singapore-based Memiontec has been developing complete water and wastewater management solutions in China, Indonesia, and Singapore for 20 years. Governmental institutions, such as the infrastructure developer Jakpro or the Indonesian national water authority PDAM, are among the Company's clientele, as are private companies from a wide range of Asian industries. In addition to the provision of total solutions, including maintenance contracts and the sale of modular and customized systems and equipment, the "Build-Own-Operate-Transfer" (BOOT) and "Transfer-Own-Operate-Transfer" (TOOT) segments are the yield drivers.

    Through long-term partnerships with public and private partners, investments are made here in the maintenance of water treatment infrastructure. By selling purified water, Memiontec benefits here in two ways. In addition to revenue from operations, maintenance and services, the Singapore company generates revenue through the sale of purified water. As the concession contracts have an average term of 25 years, recurring income is thus secured in the long term.

    25% Dividend and Records

    Memiontec plans to establish further joint ventures of this kind in the coming months. In addition, the Company also intends to grow further inorganically. As of the end of July, a record order book of EUR 58.38 million was already reported, and Memiontec also secured an order worth a total of EUR 8.09 million from Singapore's Public Utilities Board. The topic of water treatment is likely to become increasingly important in the coming years, also on the stock market. In particular, Memiontec is expected to gain further importance in the Asian region. Due to the recurring income from the TOOT and BOOT projects, the dividend yield of 25% is outstanding. It should be maintained, at least in the coming years.

    Leverage through hydrogen

    Known as a diversified industrial group focused on steel processing, ThyssenKrupp is Germany's largest steel producer. The group was formed in 1999 from the merger of Friedrich Krupp AG Hoesch-Krupp with Thyssen AG. However, the Essen-based company is also focusing on renewable energies, and the news of a planned IPO in the hydrogen sector could significantly boost its share price.

    ThyssenKrupp was looking into a listing of its Uhde Chlorine Engineers joint venture in the first quarter of 2022, Bloomberg news agency reported, citing people familiar with the situation. The listing could be worth up to EUR 5 billion. Bloomberg reported that the DAX-listed Company had initially planned to take Uhde, a joint venture with Italian industrial De Nora, public, through a special acquisition company before deciding to go the IPO route. Meanwhile, Baader Bank reiterated its Buy recommendation for ThyssenKrupp with a price target of EUR 16.

    Still at the beginning

    The advance praise for Everfuel, a spin-off of Norwegian hydrogen specialist Nel ASA, is high, with a stock market valuation of EUR 472.77 million. The focus is clearly on the future and the vision of making green hydrogen commercially available for zero-emission mobility across Europe. Based on the third-quarter figures, one can see that Everfuel is still in the early stages of commercializing the green hydrogen value chain in its target markets.

    The Danes generated total revenue during the period, with hydrogen sales and other operating income, amounting to EUR 149 thousand in the third quarter of 2021. Direct hydrogen sales continued to be held back by the decline in COVID-19 traffic and reduced capacity. The opening of the new high-capacity refueling station in Copenhagen was postponed until the fourth quarter. EBITDA was negative at EUR 1.8 million, as expected.


    It is high time to implement the climate targets that have been set. Global warming continues to progress and is leading to a dramatic shortage of water. Memiontec is countering this problem with its water treatment systems and is attractive in the long term. ThyssenKrupp has impact through its involvement in the hydrogen sector, Everfuel has yet to justify its high valuation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read